drugset / Trial / NCT01357798

Botulinum Toxin Type A in Treatment of Cranial Allodynia in Patients With Headache

NCT01357798

Phase 3 Completed 40 enrolled Federal University of Bahia
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is evaluated if the Botulinum Toxin Type A is superior to 0,9% saline in treatment of cranial Allodynia in patients with headache. Hypothesis H(0): Botulinum Toxin Type A is not superior to 0,9% saline in treatment of cranial Allodynia in patients with headache H (1): Botulinum Toxin Type A is superior to 0,9% saline in treatment of cranial Allodynia in patients with headache

Timeline

Start
2010-12
Primary completion
2011-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic